2021
Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation
Chan L, Hurtz C, Leveille E, Kume K, Robinson M, Geng H, Cosgun K, Müschen M. Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation. Blood 2021, 138: 792. DOI: 10.1182/blood-2021-148653.Peer-Reviewed Original ResearchRAS-ERK pathwayB cell developmentNormal B cell developmentRAS-ERKCell deathTransplant recipient miceSynthetic lethalityGenetic lesionsBCL6 expressionGenetic ablationChIP-seq analysisRAS-ERK signalingPermanent activationMurine B cell precursorsB cell precursorsDeletion of Bcl6Pharmacological inhibitionDoxycycline-inducible expressionSmall molecule inhibitionNegative B cell selectionSmall molecule inhibitorsExpression of PRDM1BCL6 promoterB-cell transformationExpression of BCL6
2007
The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells.
Duy C, de Alboran I, Jumaa H, Muschen M. The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells. Blood 2007, 110: 797. DOI: 10.1182/blood.v110.11.797.797.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaBCR-ABL1B cellsDownregulation of MYCImmature B cellsEarly B cell developmentB cell differentiationLymphoblastic leukemiaExpression of MYCB cell developmentNovo expressionLarge B-cell lymphomaBCR-ABL1 inhibitorsB-cell lymphomaGerminal center B cellsB-cell malignanciesDe novo expressionCell lymphomaBone marrowPre-B cell culturesPre B cellsLeukemic transformationInduction of differentiationIL7Expression of BCL6